First‐in‐man allopregnanolone use in super‐refractory status epilepticus

Super‐refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaitkevicius, Henrikas, Husain, Aatif M., Rosenthal, Eric S., Rosand, Jonathan, Bobb, Wendell, Reddy, Kiran, Rogawski, Michael A., Cole, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454395/
https://www.ncbi.nlm.nih.gov/pubmed/28589168
http://dx.doi.org/10.1002/acn3.408
_version_ 1783240824490819584
author Vaitkevicius, Henrikas
Husain, Aatif M.
Rosenthal, Eric S.
Rosand, Jonathan
Bobb, Wendell
Reddy, Kiran
Rogawski, Michael A.
Cole, Andrew J.
author_facet Vaitkevicius, Henrikas
Husain, Aatif M.
Rosenthal, Eric S.
Rosand, Jonathan
Bobb, Wendell
Reddy, Kiran
Rogawski, Michael A.
Cole, Andrew J.
author_sort Vaitkevicius, Henrikas
collection PubMed
description Super‐refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABA(A) receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a 120‐h continuous infusion of allopregnanolone. Both patients recovered from prolonged SRSE with good cognitive outcomes.
format Online
Article
Text
id pubmed-5454395
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54543952017-06-06 First‐in‐man allopregnanolone use in super‐refractory status epilepticus Vaitkevicius, Henrikas Husain, Aatif M. Rosenthal, Eric S. Rosand, Jonathan Bobb, Wendell Reddy, Kiran Rogawski, Michael A. Cole, Andrew J. Ann Clin Transl Neurol Brief Communications Super‐refractory status epilepticus (SRSE) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABA(A) receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a 120‐h continuous infusion of allopregnanolone. Both patients recovered from prolonged SRSE with good cognitive outcomes. John Wiley and Sons Inc. 2017-04-26 /pmc/articles/PMC5454395/ /pubmed/28589168 http://dx.doi.org/10.1002/acn3.408 Text en © 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Vaitkevicius, Henrikas
Husain, Aatif M.
Rosenthal, Eric S.
Rosand, Jonathan
Bobb, Wendell
Reddy, Kiran
Rogawski, Michael A.
Cole, Andrew J.
First‐in‐man allopregnanolone use in super‐refractory status epilepticus
title First‐in‐man allopregnanolone use in super‐refractory status epilepticus
title_full First‐in‐man allopregnanolone use in super‐refractory status epilepticus
title_fullStr First‐in‐man allopregnanolone use in super‐refractory status epilepticus
title_full_unstemmed First‐in‐man allopregnanolone use in super‐refractory status epilepticus
title_short First‐in‐man allopregnanolone use in super‐refractory status epilepticus
title_sort first‐in‐man allopregnanolone use in super‐refractory status epilepticus
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454395/
https://www.ncbi.nlm.nih.gov/pubmed/28589168
http://dx.doi.org/10.1002/acn3.408
work_keys_str_mv AT vaitkeviciushenrikas firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT husainaatifm firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT rosenthalerics firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT rosandjonathan firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT bobbwendell firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT reddykiran firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT rogawskimichaela firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus
AT coleandrewj firstinmanallopregnanoloneuseinsuperrefractorystatusepilepticus

Ejemplares similares